CD6 and psoriasis: In Asia, an antibody targeting CD6 expressed by Tc17 cells, itolizumab, is in clinical use for the treatment of psoriasis with the rationale of modulation of CD6-dependent signaling pathways in Tc17 cells [4, 43, 50, 229].